J. Nadal
15 Papers
19 Citations
J. Nadal is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer
E. Roca,E. Pennella,M. Sardi,S. Carraro,M. Barugel,C. Milano,A. Fiorini,R. Giglio,G. Gonzalez,R. Kneitschel,E. Aman,A. Jarentchuk,C. Blajman,J. Nadal,M.T. Santarelli,A. Navigante +15 more
TL;DR: The results appear improved over those reported with surgery or radiation alone, and suggest that organ preservation as a secondary treatment goal should be vigorously investigated.
23
LBA18 Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial
F Andre,J. Nadal,Hannelore Denys,Saroj Goel,Lacey M. Litchfield,Adams Kusi Appiah,Yi Chen,Sara M. Tolaney +7 more
TL;DR: Abemaciclib, an oral, selective CDK4 & 6 inhibitor, significantly improved PFS in HR+, HER2+ advanced breast cancer (ABC; locoregionally recurrent or metastatic) when combined with fulvestrant and trastuzumab, compared to trastusumab plus chemotherapy in monarcHER as mentioned in this paper .
17
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.
Francesco Passamonti,Florian H. Heidel,Rohan Parikh,Mayank Ajmera,Derek Tang,J. Nadal,Keith L. Davis,Pranav Abraham +7 more
TL;DR: There is an unmet need for more effective treatments for patients with myelofibrosis who failed ruxolitinib, according to the results of this large, real-world study.
13
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
U. Platzbecker,Valeria Santini,Rami S. Komrokji,Amer M. Zeidan,Guillermo Garcia-Manero,Rena Buckstein,Dimana O. Miteva,K. Keeperman,Natalia Holot,J. Nadal,Yinzhi Lai,S. Vodala,Barbara Rosettani,Ana Carolina Giuseppi,Aylin Yucel,Pierre Fenaux +15 more
TL;DR: Erythropoiesis-stimulating agents (ESAs) are used to treat anemia in patients with LR-MDS with serum erythropoietin (EPO) levels ≤ 500 U/l and low transfusion burden, however, the median duration of response to ESAs is shorter than that of other treatments.
4